Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 43, Issue 7, Pages 683-691Publisher
WILEY
DOI: 10.1177/0091270003254637
Keywords
dichloroacetate; lactate; lactic acidosis; meta-analysis
Categories
Funding
- NCRR NIH HHS [M01 RR00082] Funding Source: Medline
- NIEHS NIH HHS [R01 ES07355, P42 ES 07375] Funding Source: Medline
- FDA HHS [FD-R-001500] Funding Source: Medline
Ask authors/readers for more resources
Dichloroacetate (DCA) decreases blood, cerebral spinal fluid, and intracellular lactate concentrations by activating the mitochondrial pyruvate dehydrogenose enzyme complex. The authors reviewed the efficacy of this investigational drug in the treatment of acquired or congenital forms of lactic acidosis from data in 40 English-language publications. The hypolactatemic effect of DCA occurs over a broad range of pretreatment lactate concentrations and is directly related to the baseline lactate level. The maximum lactate-lowering effect of the drug is dependent on its dose but independent of time following its administration. Recent clinical studies of acquired lactic acidosis suggest that DCA could be rapidly effective in reducing this risk factor of mortality in patients with mild hyperlactatemeia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available